SYRE
Spyre Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$97.33-2.89%
Price as of Jul 20, 2026
SYRE financials
Spyre Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $886.0K | $2.3M |
| Cost of revenue | $171.7M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$171.7M | $0.00 | $886.0K | $2.3M |
| Operating expenses | $37.9M | $208.6M | $243.2M | $87.1M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M |
| EBITDA | -$209.6M | -$208.0M | -$127.6M | -$82.0M |
| Basic EPS | $-1.98 | $-3.18 | $-46.15 | $-24.86 |
| Diluted EPS | $-1.98 | $-3.18 | $-46.15 | $-24.86 |
| Balance sheet | ||||
| Cash & equivalents | $85.7M | $89.4M | $188.9M | $34.9M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M |
| Total liabilities | $62.5M | $90.7M | $157.8M | $20.8M |
| Stockholders’ equity | $715.2M | $517.8M | $184.0M | $50.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $4.6M |
| Net debt | -$85.7M | -$89.4M | -$188.9M | -$30.2M |
| Cash flow | ||||
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | -$38.0K |
| Free cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |